Dr. Corn on Possibility of Immunotherapy for Patients With Prostate Cancer

Paul G. Corn, MD, PhD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the possibility of immunotherapy in patients with prostate cancer.

While impressive data have not been reported thus far, researchers still believe that checkpoint inhibitors hold great promise in treating castration-resistant prostate cancer, Corn explains. Although phase III studies were found to be statistically negative, it is clear that a subset of patients does benefit, at least with the use of ipilimumab (Yervoy).

A combination of these drugs may be required. Corn says these checkpoint inhibitors will prove to be an incredibly important avenue of research.